CD19 and neoplasm: Jamali et al. revealed that the lentiviral vector-mediated engineering of NK cells to express CD19 CAR and CXCR4 increases their migration into the tumor site up to two times compared to conventional CD19 CAR-NK cells without affecting their cytotoxicity (Jamali et al., 2020).